Effectiveness of a Self-Efficacy Enhancement Program on Health Behaviors and Clinical Outcomes in People with Metabolic Syndrome: A Quasi-Experimental Study in Thailand.

Effectiveness of a Self-Efficacy Enhancement Program on Health Behaviors and Clinical Outcomes in People with Metabolic Syndrome

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20250218014

Enrollment

Registered

2025-02-18

Start date

2023-09-21

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic Syndrome Metabolic Syndrome

Interventions

The experimental group received the self-efficacy enhancement program integrating self-efficacy theory (Bandura, 1997) developed by the researcher and routine nursing care from the health care provide

Experimental Behavioral,No Intervention No treatment

The Self-Efficacy Enhancement Program ,Routine nursing care

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged 18 years old or above. 2. Had MetS at least three months without complications based on a new MetS criterion (Dobrowolski et al., 2022) 3. Be able to communicate using the LINE application. 4. Ability to communicate in Thai. 5. Willingness to participate in this study.

Exclusion criteria

Exclusion criteria: 1. Participants who performed the self-efficacy enhancement program less than 80 percent. 2. Participants are admitted to the hospital due to MetS complications during the research. 3. Participants declined or withdraw from the study.

Design outcomes

Primary

Measure	Time frame
Health behaviors at week 13 after end of the intervention Patient reported outcome using a questionnaire interview,Waist circumference (WC) at week 13 after end of the intervention centimetre (cm),Systolic Blood Pressure (SBP) at week 13 after end of the intervention Millimetre of mercury (mmHg),Diastolic Blood Pressure (DBP) at week 13 after end of the intervention Millimetre of mercury (mmHg),Fasting Plasma Glucose (FPG) at week 13 after end of the intervention Milligrams per decilitre (mg/dL),Total Cholesterol level (TC) at week 13 after end of the intervention Milligrams per decilitre (mg/dL),HDL cholesterol at week 13 after end of the intervention Milligrams per decilitre (mg/dL),non HDL cholesterol at week 13 after end of the intervention Milligrams per decilitre (mg/dL)	—

Measure

Time frame

Health behaviors at week 13 after end of the intervention Patient reported outcome using a questionnaire interview,Waist circumference (WC) at week 13 after end of the intervention centimetre (cm),Systolic Blood Pressure (SBP) at week 13 after end of the intervention Millimetre of mercury (mmHg),Diastolic Blood Pressure (DBP) at week 13 after end of the intervention Millimetre of mercury (mmHg),Fasting Plasma Glucose (FPG) at week 13 after end of the intervention Milligrams per decilitre (mg/dL),Total Cholesterol level (TC) at week 13 after end of the intervention Milligrams per decilitre (mg/dL),HDL cholesterol at week 13 after end of the intervention Milligrams per decilitre (mg/dL),non HDL cholesterol at week 13 after end of the intervention Milligrams per decilitre (mg/dL)

—

Secondary

Measure	Time frame
Number of dropouts at week 13 after end of the intervention people	—

Countries

Thailand

Contacts

Public ContactChalermkwan Madsong

Srisavarindhira Thai Red Cross Institute of Nursing

chalermkwan.mad@student.mahidol.edu02256409297

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026